Torsten Kraya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Torsten Kraya has a total of 132 co-authors. Here are the top co-authors by number of shared publications:
Stephan Zierz
Martin-Luther-Universität Halle-Wittenberg
19 shared publicationsMarcus Deschauer
Technische Universität München
6 shared publicationsS. Zierz
Martin-Luther-Universität Halle-Wittenberg
5 shared publications- Gudrun Gossrau
Interdisciplinary Pain Center, University Hospital and Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany
4 shared publications Charly Gaul
Headache Center Frankfurt, Frankfurt, Germany
3 shared publicationsDietrich Stoevesandt
Department of Radiology, University Hospital Halle, Martin-Luther-University Halle- Wittenberg, Halle (Saale), Germany
3 shared publications
Latest Publications
- Open Access
- 29 September 2026
- Published by Springer Nature in The Journal of Headache and Pain
- Vol. 27 (1) , 228
In the heat of the moment: prevalence and clinical characteristics of headache associated with sexual activity (head HEATS study)
Background: Headache associated with sexual activity (HAS) is an uncommon and understudied primary headache disorder. Previous epidemiological studies have estimated a lifetime prevalence of approximately 1.0–1.6%, although the true prevalence remains uncertain because symptoms related to sexual activity may be underreported. Objective: This study aimed to assess the prevalence and clinical characteristics of HAS and its co-occurrence with other primary headache disorders in a university-based cohort. Methods: A cross-sectional questionnaire study was conducted among students and employees at Martin- Luther-University Halle-Wittenberg, Germany. Of 1213 distributed questionnaires, 606 with complete age and sex information were included in the final analysis. Continuous variables were assessed for normality and compared using non-parametric methods when appropriate. Categorical variables were compared using two-sided Fisher’s exact tests. Associations with HAS were explored using parsimonious Firth penalized logistic regression models. Results: Twenty-three of 606 participants reported HAS, corresponding to a lifetime prevalence of 3.8% (95% CI, 2.6–5.6%). Participants with HAS were older than those without HAS (median [IQR], 25 [21–34.5] vs. 21 [19–26] years; p = 0.005). Although 82.6% of participants with HAS were female, the proportion did not differ significantly between groups (82.6% vs. 68.6%; p = 0.175). Among participants with available timing data, headache occurred during sexual arousal or the buildup to orgasm in 57.9% and at orgasm in 42.1%. Clinical characteristics were heterogeneous with respect to pain quality and localization, and symptoms compatible with migraine aura were reported by 34.7%. Migraine and tension-type headache were not significantly associated with HAS. In age- and sex-adjusted Firth penalized logistic regression, primary exercise headache was associated with higher odds of HAS (aOR 4.06, 95% CI 1.41–11.72; p = 0.010). Conclusions: In this university-based questionnaire study, 3.8% of participants reported symptoms compatible with HAS. The clinical presentation was heterogeneous, and primary exercise headache was associated with higher odds of HAS after adjustment for age and sex. Given the small number of HAS cases, questionnaire-based case ascertainment, and potential selection and response bias, these findings should be considered exploratory and should not be interpreted as population-representative prevalence estimates. Larger studies using clinician-confirmed diagnoses are needed to validate these findings.
- 29 September 2026
- Published by Springer Nature in The Journal of Headache and Pain
- Vol. 27 (1) , 228
Open AccessIn the heat of the moment: prevalence and clinical characteristics of headache associated with sexual activity (head HEATS study)
Background: Headache associated with sexual activity (HAS) is an uncommon and understudied primary headache disorder. Previous epidemiological studies have estimated a lifetime prevalence of approximately 1.0–1.6%, although the true prevalence remains uncertain because symptoms related to sexual activity may be underreported. Objective: This study aimed to assess the prevalence and clinical characteristics of HAS and its co-occurrence with other primary headache disorders in a university-based cohort. Methods: A cross-sectional questionnaire study was conducted among students and employees at Martin- Luther-University Halle-Wittenberg, Germany. Of 1213 distributed questionnaires, 606 with complete age and sex information were included in the final analysis. Continuous variables were assessed for normality and compared using non-parametric methods when appropriate. Categorical variables were compared using two-sided Fisher’s exact tests. Associations with HAS were explored using parsimonious Firth penalized logistic regression models. Results: Twenty-three of 606 participants reported HAS, corresponding to a lifetime prevalence of 3.8% (95% CI, 2.6–5.6%). Participants with HAS were older than those without HAS (median [IQR], 25 [21–34.5] vs. 21 [19–26] years; p = 0.005). Although 82.6% of participants with HAS were female, the proportion did not differ significantly between groups (82.6% vs. 68.6%; p = 0.175). Among participants with available timing data, headache occurred during sexual arousal or the buildup to orgasm in 57.9% and at orgasm in 42.1%. Clinical characteristics were heterogeneous with respect to pain quality and localization, and symptoms compatible with migraine aura were reported by 34.7%. Migraine and tension-type headache were not significantly associated with HAS. In age- and sex-adjusted Firth penalized logistic regression, primary exercise headache was associated with higher odds of HAS (aOR 4.06, 95% CI 1.41–11.72; p = 0.010). Conclusions: In this university-based questionnaire study, 3.8% of participants reported symptoms compatible with HAS. The clinical presentation was heterogeneous, and primary exercise headache was associated with higher odds of HAS after adjustment for age and sex. Given the small number of HAS cases, questionnaire-based case ascertainment, and potential selection and response bias, these findings should be considered exploratory and should not be interpreted as population-representative prevalence estimates. Larger studies using clinician-confirmed diagnoses are needed to validate these findings.
- Open Access
- 14 September 2026
- Published by JMIR Publications Inc. in JMIR mHealth and uHealth
- Vol. 14, e73259
Daily Reminders Increase Adherence to an Electronic Headache Diary (DMKG-App): Retrospective Longitudinal Cohort Study
Background: The use of electronic headache diaries via smartphone apps has several advantages over paper and pencil diaries. Still, adherence is not always satisfactory. One potential strategy to improve adherence is the implementation of daily reminders, but their effect remains uncertain. Objective: The DMKG-App (the headache diary app of the German Migraine and Headache Society, DMKG) sends daily reminders to encourage user adherence. Due to a technical problem, reminders failed for a 14-day period in early 2023. This provided a unique opportunity to evaluate the effect of daily reminders on adherence to the headache diary in the form of a retrospective longitudinal observational cohort study. Methods: The failure period was compared to 14-day prefailure and postfailure periods and to corresponding periods of the previous year. We evaluated effects on the number of daily entries, delay to make the daily entry, and attrition rate, using ANOVA and logistic regression (α<.05). The effect of age, gender, headache frequency, and previous adherence was investigated using interaction analysis. Results: The DMKG-App had 4236 active users before reminders failed (females 81.6%, 95% CI 80.5‐82.8), age 39.8 (95% CI 39.4‐40.2) years. During the failure period, the number of daily entries fell by 11.0% (95% CI 9.2‐12.8). More specifically, entries per 14-day period significantly declined from 10.2 (95% CI 10.1‐10.3) prefailure to 9.1 (95% CI 9.0‐9.2) during the failure period, followed by a rise to 10.2 (95% CI 10.1‐10.3) during the postfailure period ( F 2,11498 =79.2; P <.001). The delay to make the daily entry increased by 46.3% (95% CI 45.8‐46.8), from 1.90 (95% CI 1.89‐1.90) days prefailure to 2.78 (95% CI 2.77‐2.79) days during failure, and returned to 1.85 (95% CI 1.84‐1.86) days postfailure ( F 2,39 =155.4 ; P <.001). In addition, there was a significant rise in attrition rate by 32.2% (95% CI 8.1‐61.7) (from 4.0%, 95% CI 3.4‐4.6, in the prefailure period to 5.2%, 95% CI 4.6‐5.9, in the failure period, returning to 3.9%, 95% CI 3.4‐4.5, in the postfailure period, z =3.10; P =.002). Interaction analysis revealed that the effect of reminder failure was larger in males than in females (regarding entry delay), in persons with lower compared to higher headache frequencies (regarding number of daily entries and entry delay), and in persons with higher vs lower previous adherence rates (regarding number of daily entries, entry delay, and attrition). There was no interaction between age and reminder failure. Conclusions: This is the first study investigating the effect of daily reminders in a digital headache diary app. Results suggest that reminders are an effective means to improve adherence. Males, persons with low headache frequencies, and those with high adherence during the presence of reminders seem to benefit most. These results are important additions to our knowledge on compliance with digital health apps.
- 14 September 2026
- Published by JMIR Publications Inc. in JMIR mHealth and uHealth
- Vol. 14, e73259
Open AccessDaily Reminders Increase Adherence to an Electronic Headache Diary (DMKG-App): Retrospective Longitudinal Cohort Study
Background: The use of electronic headache diaries via smartphone apps has several advantages over paper and pencil diaries. Still, adherence is not always satisfactory. One potential strategy to improve adherence is the implementation of daily reminders, but their effect remains uncertain. Objective: The DMKG-App (the headache diary app of the German Migraine and Headache Society, DMKG) sends daily reminders to encourage user adherence. Due to a technical problem, reminders failed for a 14-day period in early 2023. This provided a unique opportunity to evaluate the effect of daily reminders on adherence to the headache diary in the form of a retrospective longitudinal observational cohort study. Methods: The failure period was compared to 14-day prefailure and postfailure periods and to corresponding periods of the previous year. We evaluated effects on the number of daily entries, delay to make the daily entry, and attrition rate, using ANOVA and logistic regression (α<.05). The effect of age, gender, headache frequency, and previous adherence was investigated using interaction analysis. Results: The DMKG-App had 4236 active users before reminders failed (females 81.6%, 95% CI 80.5‐82.8), age 39.8 (95% CI 39.4‐40.2) years. During the failure period, the number of daily entries fell by 11.0% (95% CI 9.2‐12.8). More specifically, entries per 14-day period significantly declined from 10.2 (95% CI 10.1‐10.3) prefailure to 9.1 (95% CI 9.0‐9.2) during the failure period, followed by a rise to 10.2 (95% CI 10.1‐10.3) during the postfailure period ( F 2,11498 =79.2; P <.001). The delay to make the daily entry increased by 46.3% (95% CI 45.8‐46.8), from 1.90 (95% CI 1.89‐1.90) days prefailure to 2.78 (95% CI 2.77‐2.79) days during failure, and returned to 1.85 (95% CI 1.84‐1.86) days postfailure ( F 2,39 =155.4 ; P <.001). In addition, there was a significant rise in attrition rate by 32.2% (95% CI 8.1‐61.7) (from 4.0%, 95% CI 3.4‐4.6, in the prefailure period to 5.2%, 95% CI 4.6‐5.9, in the failure period, returning to 3.9%, 95% CI 3.4‐4.5, in the postfailure period, z =3.10; P =.002). Interaction analysis revealed that the effect of reminder failure was larger in males than in females (regarding entry delay), in persons with lower compared to higher headache frequencies (regarding number of daily entries and entry delay), and in persons with higher vs lower previous adherence rates (regarding number of daily entries, entry delay, and attrition). There was no interaction between age and reminder failure. Conclusions: This is the first study investigating the effect of daily reminders in a digital headache diary app. Results suggest that reminders are an effective means to improve adherence. Males, persons with low headache frequencies, and those with high adherence during the presence of reminders seem to benefit most. These results are important additions to our knowledge on compliance with digital health apps.
- Open Access
- 10 February 2025
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 20 (1) , 1-7
Cardiac manifestations in adult MELAS syndrome (mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes syndrome)– a cross-sectional study
Backround: Cardiac involvement has been reported in different mitochondrial geno- and phenotypes, including mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like (MELAS) syndrome. However, cardiac manifestations are diverse and not well described. Methods: We prospectively examined cardiac manifestations in 11 adult patients with MELAS syndrome harboring the MTTL1 m.3243A < G-mutation using patient records, cardiac MRI (1.5 Tesla), echocardiography, electrocardiogram (ECG), laboratory tests of cardiac markers (CK, CK-MB, Trop I, BNP), and clinical severity (NMDAS = Newcastle Mitochondrial Disease Scale). Results: Among 11 consecutive patients with MELAS syndrome (73% male, mean age 37.5 ± 10.6 years) cardiac manifestations were found in nine (82%). Pathology was mainly detected using MRI (9 of 11, 82%). Six patients showed diffuse late enhancement in the left ventricle, one a left ventricular ejection fraction (LVEF) below 30%, two with a LVEF in the range of 40–50% in the cardiac MRI, and another five patients presenting diastolic dysfunction as defined by echocardiography. Only one patient with late enhancement on MRI also showed a conduction block in the ECG. There was no correlation between the cardiac manifestations and the NMDAS score or heteroplasmy grade. Conclusions: Cardiac involvement in MELAS syndrome harboring the MTTL1 m.3243A > G mutation mostly entails cardiomyopathy, which was particularly evident in the cardiac MRI. Only one patient (1/11, 9.1%) had conduction defects. Thus, cardiac testing including cardiac MRI, echocardiography and ECG seems to be important for prognosis of MELAS patients.
- 10 February 2025
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 20 (1) , 1-7
Open AccessCardiac manifestations in adult MELAS syndrome (mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes syndrome)– a cross-sectional study
Backround: Cardiac involvement has been reported in different mitochondrial geno- and phenotypes, including mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like (MELAS) syndrome. However, cardiac manifestations are diverse and not well described. Methods: We prospectively examined cardiac manifestations in 11 adult patients with MELAS syndrome harboring the MTTL1 m.3243A < G-mutation using patient records, cardiac MRI (1.5 Tesla), echocardiography, electrocardiogram (ECG), laboratory tests of cardiac markers (CK, CK-MB, Trop I, BNP), and clinical severity (NMDAS = Newcastle Mitochondrial Disease Scale). Results: Among 11 consecutive patients with MELAS syndrome (73% male, mean age 37.5 ± 10.6 years) cardiac manifestations were found in nine (82%). Pathology was mainly detected using MRI (9 of 11, 82%). Six patients showed diffuse late enhancement in the left ventricle, one a left ventricular ejection fraction (LVEF) below 30%, two with a LVEF in the range of 40–50% in the cardiac MRI, and another five patients presenting diastolic dysfunction as defined by echocardiography. Only one patient with late enhancement on MRI also showed a conduction block in the ECG. There was no correlation between the cardiac manifestations and the NMDAS score or heteroplasmy grade. Conclusions: Cardiac involvement in MELAS syndrome harboring the MTTL1 m.3243A > G mutation mostly entails cardiomyopathy, which was particularly evident in the cardiac MRI. Only one patient (1/11, 9.1%) had conduction defects. Thus, cardiac testing including cardiac MRI, echocardiography and ECG seems to be important for prognosis of MELAS patients.
- Open Access
- 21 July 2024
- Published by SAGE Publications in Cephalalgia
- Vol. 44 (7)
Minimal important difference of the Migraine Disability Assessment (MIDAS): Longitudinal data from the DMKG Headache Registry
Background: The Migraine Disability Assessment (MIDAS) is widely used. However, there are limited data on how much a reduction in the MIDAS score indicates a change that matters to the patient. Methods: Data from the DMKG (i.e. German Migraine and Headache Society) Headache Registry were used to determine the minimal important difference (MID) of the MIDAS, using the Patient Global Impression of Change (PGIC) as anchor and applying average change and receiver operating characteristic curve methods. Results: In total, 1218 adult migraine patients (85.6% female, 40.2 ± 12.8 years, baseline MIDAS 44.2 ± 47.4, follow-up MIDAS 36.5 ± 45.3) were included. For patients with baseline MIDAS >20 (MIDAS grade IV, n = 757), different methods using PGIC “somewhat improved” as anchor yielded percent change MIDs of the MIDAS between −29.4% and −33.2%. For baseline MIDAS between 6 and 20 (grades II and III, n = 334), using PGIC “much improved” as anchor, difference change MIDs were between −3.5 and −4.5 points. Conclusions: Based on the above results, we estimated the MID of the MIDAS at −30% for patients with a baseline MIDAS >20, and at −4 points for those with a baseline MIDAS of 6–20, for a tertiary headache care population. Trial Registration: The DMKG Headache Registry is registered with the German Clinical Trials Register (DRKS 00021081).
- 21 July 2024
- Published by SAGE Publications in Cephalalgia
- Vol. 44 (7)
Open AccessMinimal important difference of the Migraine Disability Assessment (MIDAS): Longitudinal data from the DMKG Headache Registry
Background: The Migraine Disability Assessment (MIDAS) is widely used. However, there are limited data on how much a reduction in the MIDAS score indicates a change that matters to the patient. Methods: Data from the DMKG (i.e. German Migraine and Headache Society) Headache Registry were used to determine the minimal important difference (MID) of the MIDAS, using the Patient Global Impression of Change (PGIC) as anchor and applying average change and receiver operating characteristic curve methods. Results: In total, 1218 adult migraine patients (85.6% female, 40.2 ± 12.8 years, baseline MIDAS 44.2 ± 47.4, follow-up MIDAS 36.5 ± 45.3) were included. For patients with baseline MIDAS >20 (MIDAS grade IV, n = 757), different methods using PGIC “somewhat improved” as anchor yielded percent change MIDs of the MIDAS between −29.4% and −33.2%. For baseline MIDAS between 6 and 20 (grades II and III, n = 334), using PGIC “much improved” as anchor, difference change MIDs were between −3.5 and −4.5 points. Conclusions: Based on the above results, we estimated the MID of the MIDAS at −30% for patients with a baseline MIDAS >20, and at −4 points for those with a baseline MIDAS of 6–20, for a tertiary headache care population. Trial Registration: The DMKG Headache Registry is registered with the German Clinical Trials Register (DRKS 00021081).
- 6 May 2022
- Published by Springer Nature in MMW - Fortschritte der Medizin
- Vol. 164 (9) , 53-57
Mit vereinten Daten gegen den Kopfschmerz
- 6 May 2022
- Published by Springer Nature in MMW - Fortschritte der Medizin
- Vol. 164 (9) , 53-57
Mit vereinten Daten gegen den Kopfschmerz
- 29 September 2020
- Published by Springer Nature
- p. 347-363
Progressive Muskeldystrophien und kongenitale Myopathien
- 29 September 2020
- Published by Springer Nature
- p. 347-363
Progressive Muskeldystrophien und kongenitale Myopathien
- 29 September 2020
- Published by Springer Nature
- p. 403-407
Endokrine Myopathien
- 29 September 2020
- Published by Springer Nature
- p. 365-374
Myotonien und Ionenkanalerkrankungen
- Open Access
- 5 May 2020
- Published by Georg Thieme Verlag KG in Nervenheilkunde
- Vol. 39 (05) , 340-343
Kopfschmerz News der DMKG
**** Oskoui M, Pringsheim T, Billinghurst L, et al. Practice guideline update summary: Pharmacologic treatment for pediatric migraine prevention. Neurology 2019; 93: 500–509 In diesem Bericht des Unterkomitees der American Academy of Neurology und der American Headache Society werden aktualisierte evidenzbasierte Empfehlungen zur Prävention der Migräne im Kindes- und Jugendalter bereitgestellt. Insbesondere wird auf die pharmakologische Migräneprophylaxe mit oder ohne kognitive Verhaltenstherapie (KVT) eingegangen. Die Autoren überprüften und klassifizierten systematisch die Literatur von Januar 2003 bis August 2017. Placebokontrollierte Studien zu pharmakologischen Interventionen, auch unter zusätzlicher Anwendung von KVT als präventive Migränetherapien für Kinder und Jugendliche im Alter von 3 bis 18 Jahren wurden in diese systematische Übersicht aufgenommen. 15 Studien der Klassen I bis III zur Migräneprävention bei Kindern und Jugendlichen erfüllten die Einschlusskriterien. Es gibt keine ausreichende Evidenz dafür, dass Valproinsäure, Onabotulinumtoxin A, Amitriptylin, Nimodipin oder Flunarizin für Kinder und Jugendliche mit Migräne eine Reduktion der Kopfschmerzhäufigkeit wahrscheinlicher als Placebo bewirken. Bei Kindern mit Migräne, die Propranolol erhalten, ist die Wahrscheinlichkeit einer mindestens 50 %igen Reduktion der Kopfschmerzhäufigkeit möglicherweise höher als bei Kindern, die ein Placebo erhalten. Kinder und Jugendliche, die Topiramat oder Cinnarizin erhalten, haben eine höhere Wahrscheinlichkeit, dass die Kopfschmerzhäufigkeit abnimmt als diejenigen, die ein Placebo erhalten. Bei Kindern mit Migräne, die Amitriptylin plus KVT erhalten, ist die Wahrscheinlichkeit einer Kopfschmerzreduktion höher als bei Kindern, die Amitriptylin plus Kopfschmerzedukation erhalten. Nach diesen Daten ist es möglich, dass die KVT allein effektiv in der Migräneprävention wirkt. Die Datenlage reicht zur Beurteilung eines unabhängigen migräneprophylaktischen Effektes von Amitriptylin bei Kindern und Jugendlichen nicht aus. Darüber hinaus existiert eine Warnung der FDA bezüglich des erhöhten Suizidrisikos nach Einsatz von Amitriptylin bei Kindern, Jugendlichen und junge Erwachsenen (www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/suicidality-children-and-adolescents-being-treated-antidepressant-medications). Die meisten Studien, die die Wirksamkeit von präventiven Medikamenten für pädiatrische Migräne untersuchen, können keine Überlegenheit gegenüber Placebo zeigen. Zu den Praxisempfehlungen für die Prävention von Migräne bei Kindern und Jugendlichen gehören die Beratung zu Lebensstil- und Verhaltensfaktoren sowie die Beurteilung und Behandlung von komorbiden psychischen Erkrankungen, die einen Einfluss auf die Kopfschmerzhäufigkeit haben können. Kliniker sollten gemeinsam mit Patienten und Erziehungsberechtigten Entscheidungen über die Anwendung präventiver Migränebehandlungen treffen und dabei auch die Grenzen der Evidenz pharmakologischer Therapien berücksichtigen. Diese Arbeit fasst die begrenzte Datenlage zur medikamentösen Migräneprophylaxe bei Kindern und Jugendlichen zusammen. Die wenigen, qualitativ wertigen placebokontrollierten Studien zur medikamentösen Migräneprophylaxe bei Kindern und Jugendlichen fallen mehrheitlich negativ aus. Hauptgrund dafür ist die hohe Placeborate von 30–60 % bei Kindern und Jugendlichen, weshalb Effekte der Verumpräparate sich nicht mehr abheben. Die explizite Empfehlung zur Einschätzung komorbider psychischer Erkrankungen als Risikofaktor einer Kopfschmerzchronifizierung im Kindes- und Jugendalter ist sehr wichtig. In diesem Kontext wird der Stellenwert von verhaltenstherapeutischen Interventionen zur Migräneprophylaxe herausgearbeitet. Es bleibt die Notwendigkeit, die Wirksamkeit von KVT als Migräneprophylaxe zukünftig durch gut konzipierte Studien weiter zu unterlegen. Insgesamt unterstreicht diese Übersicht erneut die Notwendigkeit einer komplexen interdisziplinären Behandlung junger Migränepatienten, wo neben Edukation zu Erkrankung und Lebensstil auch die Einschätzung psychischer Komorbiditäten und deren Therapie erfolgen muss. Die vorhandene Evidenz für Topiramat, Cinnarizin und Propranolol zur Prophylaxe der Migräne bei Kindern und Jugendlichen bildet die Rationale für Therapieversuche bei jenen Patienten, die trotz nicht medikamentöser Migräneprophylaxen weiterhin unter häufigen Migräneattacken leiden und massive Alltagseinschränkungen zeigen. Für diese Patienten können medikamentöse Migräneprophylaxen wie Topiramat und Amitriptylin bei differenziertem Einsatz eine deutliche Verbesserung der Alltagsfunktion bewirken. Wichtig ist, die medikamentöse Behandlung in ein interdisziplinäres Therapiekonzept zu integrieren und Therapiesicherheit sowie Therapieeffekte regelmäßig zu prüfen, z. B. Kopfschmerztagebuch. Gudrun Goßrau, Dresden
- 5 May 2020
- Published by Georg Thieme Verlag KG in Nervenheilkunde
- Vol. 39 (05) , 340-343
Open AccessKopfschmerz News der DMKG
**** Oskoui M, Pringsheim T, Billinghurst L, et al. Practice guideline update summary: Pharmacologic treatment for pediatric migraine prevention. Neurology 2019; 93: 500–509 In diesem Bericht des Unterkomitees der American Academy of Neurology und der American Headache Society werden aktualisierte evidenzbasierte Empfehlungen zur Prävention der Migräne im Kindes- und Jugendalter bereitgestellt. Insbesondere wird auf die pharmakologische Migräneprophylaxe mit oder ohne kognitive Verhaltenstherapie (KVT) eingegangen. Die Autoren überprüften und klassifizierten systematisch die Literatur von Januar 2003 bis August 2017. Placebokontrollierte Studien zu pharmakologischen Interventionen, auch unter zusätzlicher Anwendung von KVT als präventive Migränetherapien für Kinder und Jugendliche im Alter von 3 bis 18 Jahren wurden in diese systematische Übersicht aufgenommen. 15 Studien der Klassen I bis III zur Migräneprävention bei Kindern und Jugendlichen erfüllten die Einschlusskriterien. Es gibt keine ausreichende Evidenz dafür, dass Valproinsäure, Onabotulinumtoxin A, Amitriptylin, Nimodipin oder Flunarizin für Kinder und Jugendliche mit Migräne eine Reduktion der Kopfschmerzhäufigkeit wahrscheinlicher als Placebo bewirken. Bei Kindern mit Migräne, die Propranolol erhalten, ist die Wahrscheinlichkeit einer mindestens 50 %igen Reduktion der Kopfschmerzhäufigkeit möglicherweise höher als bei Kindern, die ein Placebo erhalten. Kinder und Jugendliche, die Topiramat oder Cinnarizin erhalten, haben eine höhere Wahrscheinlichkeit, dass die Kopfschmerzhäufigkeit abnimmt als diejenigen, die ein Placebo erhalten. Bei Kindern mit Migräne, die Amitriptylin plus KVT erhalten, ist die Wahrscheinlichkeit einer Kopfschmerzreduktion höher als bei Kindern, die Amitriptylin plus Kopfschmerzedukation erhalten. Nach diesen Daten ist es möglich, dass die KVT allein effektiv in der Migräneprävention wirkt. Die Datenlage reicht zur Beurteilung eines unabhängigen migräneprophylaktischen Effektes von Amitriptylin bei Kindern und Jugendlichen nicht aus. Darüber hinaus existiert eine Warnung der FDA bezüglich des erhöhten Suizidrisikos nach Einsatz von Amitriptylin bei Kindern, Jugendlichen und junge Erwachsenen (www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/suicidality-children-and-adolescents-being-treated-antidepressant-medications). Die meisten Studien, die die Wirksamkeit von präventiven Medikamenten für pädiatrische Migräne untersuchen, können keine Überlegenheit gegenüber Placebo zeigen. Zu den Praxisempfehlungen für die Prävention von Migräne bei Kindern und Jugendlichen gehören die Beratung zu Lebensstil- und Verhaltensfaktoren sowie die Beurteilung und Behandlung von komorbiden psychischen Erkrankungen, die einen Einfluss auf die Kopfschmerzhäufigkeit haben können. Kliniker sollten gemeinsam mit Patienten und Erziehungsberechtigten Entscheidungen über die Anwendung präventiver Migränebehandlungen treffen und dabei auch die Grenzen der Evidenz pharmakologischer Therapien berücksichtigen. Diese Arbeit fasst die begrenzte Datenlage zur medikamentösen Migräneprophylaxe bei Kindern und Jugendlichen zusammen. Die wenigen, qualitativ wertigen placebokontrollierten Studien zur medikamentösen Migräneprophylaxe bei Kindern und Jugendlichen fallen mehrheitlich negativ aus. Hauptgrund dafür ist die hohe Placeborate von 30–60 % bei Kindern und Jugendlichen, weshalb Effekte der Verumpräparate sich nicht mehr abheben. Die explizite Empfehlung zur Einschätzung komorbider psychischer Erkrankungen als Risikofaktor einer Kopfschmerzchronifizierung im Kindes- und Jugendalter ist sehr wichtig. In diesem Kontext wird der Stellenwert von verhaltenstherapeutischen Interventionen zur Migräneprophylaxe herausgearbeitet. Es bleibt die Notwendigkeit, die Wirksamkeit von KVT als Migräneprophylaxe zukünftig durch gut konzipierte Studien weiter zu unterlegen. Insgesamt unterstreicht diese Übersicht erneut die Notwendigkeit einer komplexen interdisziplinären Behandlung junger Migränepatienten, wo neben Edukation zu Erkrankung und Lebensstil auch die Einschätzung psychischer Komorbiditäten und deren Therapie erfolgen muss. Die vorhandene Evidenz für Topiramat, Cinnarizin und Propranolol zur Prophylaxe der Migräne bei Kindern und Jugendlichen bildet die Rationale für Therapieversuche bei jenen Patienten, die trotz nicht medikamentöser Migräneprophylaxen weiterhin unter häufigen Migräneattacken leiden und massive Alltagseinschränkungen zeigen. Für diese Patienten können medikamentöse Migräneprophylaxen wie Topiramat und Amitriptylin bei differenziertem Einsatz eine deutliche Verbesserung der Alltagsfunktion bewirken. Wichtig ist, die medikamentöse Behandlung in ein interdisziplinäres Therapiekonzept zu integrieren und Therapiesicherheit sowie Therapieeffekte regelmäßig zu prüfen, z. B. Kopfschmerztagebuch. Gudrun Goßrau, Dresden
- 24 October 2019
- Published by SAGE Publications in Cephalalgia
- Vol. 40 (3) , 299-306
Prevalence and characteristics of headache attributed to ingestion or inhalation of a cold stimulus (HICS): A cross-sectional study
Headache attributed to ingestion or inhalation of a cold stimulus (HICS), colloquially called ice-cream headache, is a common form of a primary headache in adults and children. However, previous studies on adults are limited due to the small number of patients. Furthermore, most of the subjects in previous studies had a history of other primary headaches. Biographic data, clinical criteria of HICS and prevalence of primary headache were collected by a standardized questionnaire. A total of 1213 questionnaires were distributed; the return rate was 51.9% (n = 629); 618 questionnaires could be analyzed. In a cohort of 618 people aged between 17–63 years (females: n = 426, 68.9%), the prevalence of HICS was 51.3% (317 out of 618). There was no difference between men and women (51.3% vs. 51.6%). The duration of HICS was shorter than 30 sec in 92.7%. In the HICS group, localization of the pain was occipital in 17%. Trigemino-autonomic symptoms occurred in 22%, and visual phenomena (e.g. flickering lights, spots or lines) were reported by 18% of the HICS group. The pain intensity, but not the prevalence of HICS, was higher when tension-type headache and migraine or both were present as co-morbid primary headaches (Numeric Rating Scale (NRS) 4.58 and 6.54, p = 0.006). There was no higher risk of participants with migraine getting HICS than for those who did not have migraine (odds ratio = 1.17, 95% confidence interval (CI) 0.75–1.83; p = 0.496). The results of this study modified the current criteria for HICS in the ICHD-3 regarding duration and localization. In addition, accompanying symptoms in about one fifth of the participants are not mentioned in the ICHD-3. Neither migraine nor tension-type headache seems to be a risk factor for HICS. However, accompanying symptoms in HICS are more frequent in subjects with another primary headache than in those without such a headache.
- 24 October 2019
- Published by SAGE Publications in Cephalalgia
- Vol. 40 (3) , 299-306
Prevalence and characteristics of headache attributed to ingestion or inhalation of a cold stimulus (HICS): A cross-sectional study
Headache attributed to ingestion or inhalation of a cold stimulus (HICS), colloquially called ice-cream headache, is a common form of a primary headache in adults and children. However, previous studies on adults are limited due to the small number of patients. Furthermore, most of the subjects in previous studies had a history of other primary headaches. Biographic data, clinical criteria of HICS and prevalence of primary headache were collected by a standardized questionnaire. A total of 1213 questionnaires were distributed; the return rate was 51.9% (n = 629); 618 questionnaires could be analyzed. In a cohort of 618 people aged between 17–63 years (females: n = 426, 68.9%), the prevalence of HICS was 51.3% (317 out of 618). There was no difference between men and women (51.3% vs. 51.6%). The duration of HICS was shorter than 30 sec in 92.7%. In the HICS group, localization of the pain was occipital in 17%. Trigemino-autonomic symptoms occurred in 22%, and visual phenomena (e.g. flickering lights, spots or lines) were reported by 18% of the HICS group. The pain intensity, but not the prevalence of HICS, was higher when tension-type headache and migraine or both were present as co-morbid primary headaches (Numeric Rating Scale (NRS) 4.58 and 6.54, p = 0.006). There was no higher risk of participants with migraine getting HICS than for those who did not have migraine (odds ratio = 1.17, 95% confidence interval (CI) 0.75–1.83; p = 0.496). The results of this study modified the current criteria for HICS in the ICHD-3 regarding duration and localization. In addition, accompanying symptoms in about one fifth of the participants are not mentioned in the ICHD-3. Neither migraine nor tension-type headache seems to be a risk factor for HICS. However, accompanying symptoms in HICS are more frequent in subjects with another primary headache than in those without such a headache.